Ipilimumab, an anti-CTLA-4 antibody, was the first checkpoint inhibitor approved by the Food and Drug Administration (FDA) in 2011 for the treatment in metastatic melanoma. This evidence concerns the gene CTLA4 and metastatic melanoma.